NCT06345066View on ClinicalTrials.gov

A Study of LY3841136 in Overweight and Obese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

September 29, 2025

Study Completion Date

September 29, 2025

Conditions
ObesityOverweight
Interventions
DRUG

Tirzepatide

Administered SC.

DRUG

LY3841136

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (3)

32117

Fortrea Clinical Research Unit, Daytona Beach

53704

Fortrea Clinical Research Unit, Madison

75247

Fortrea Clinical Research Unit, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06345066 - A Study of LY3841136 in Overweight and Obese Participants | Biotech Hunter | Biotech Hunter